<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356145</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-43789</org_study_id>
    <nct_id>NCT03356145</nct_id>
  </id_info>
  <brief_title>12 Versus 20 mL PCB for D&amp;E Cervical Prep</brief_title>
  <official_title>12 Versus 20 mL Paracervical Block for Pain-Control During Cervical Preparation for Dilation and Evacuation: A Single-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      More research is needed to investigate methods of pain control for cervical preparation for&#xD;
      abortion procedures. Women report pain with paracervical block injection as well as with&#xD;
      osmotic dilator placement. This study seeks to compare a 12 mL, 2-site 1% plain lidocaine&#xD;
      paracervical block for pain control during cervical preparation (osmotic dilator insertion)&#xD;
      for Dilation and Evacuation (D&amp;E) to a 20 mL 1% lidocaine 2-site paracervical block.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-inferiority, single blinded, randomized controlled trial.This study will use a&#xD;
      2-site, 12 mL 1% plain lidocaine injection paracervical block (PCB) technique (2 mL for&#xD;
      tenaculum placement, 10 mL for paracervical block) will provide non-inferior pain control&#xD;
      compared to a previously established 2-site, 20 mL 1% lidocaine injection PCB (2 mL for&#xD;
      tenaculum placement, 18 mL for paracervical block) when administered for dilation pain&#xD;
      control during cervical preparation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to one of two study arms via computer-generated block randomization using REDCap software.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The provider and staff will be aware of arm allocation, but participants will remain blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Immediately Following Dilator Insertion</measure>
    <time_frame>Time of dilator insertion (less than 1 minute to assess pain)</time_frame>
    <description>The primary objective is to determine pain perceived immediately following dilator insertion measured by Visual Analogue Scale (VAS) (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anticipated Pain Immediately Prior to Dilator Insertion</measure>
    <time_frame>Up to 1 minute to complete survey</time_frame>
    <description>Pain measured by VAS (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Satisfaction Score</measure>
    <time_frame>Up to 1 minute to complete survey</time_frame>
    <description>Global satisfaction (acceptability) of procedure reported by participant, measured by 0-100mm VAS; with anchors at 0 (&quot;worse than expected&quot;), 50 (&quot;what I expected&quot;), and 100 (&quot;better than expected&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>Defined as time of speculum insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician-reported Ease of Insertion</measure>
    <time_frame>Up to 1 minute to complete survey</time_frame>
    <description>Measured by VAS (0-100mm; 0 being &quot;very easy&quot;, 100 being &quot;very difficult&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Procedural Complications</measure>
    <time_frame>Up to 10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Side Effects Related to Lidocaine Administration</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>Side effects were not necessarily considered to be adverse events by investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>12 mL arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:&#xD;
Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle&#xD;
2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix&#xD;
The tenaculum is immediately placed at the previously injected site&#xD;
The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)&#xD;
No wait time between injection and dilator insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mL arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention:&#xD;
Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle&#xD;
2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix&#xD;
The tenaculum is immediately placed at the previously injected site&#xD;
The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)&#xD;
No wait time between injection and dilator insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 mL paracervical block</intervention_name>
    <description>Injection of 12 mL of lidocaine</description>
    <arm_group_label>12 mL arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mL paracervical block</intervention_name>
    <description>Injection of 20 mL of lidocaine</description>
    <arm_group_label>20 mL arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18 and older&#xD;
&#xD;
          -  Intrauterine pregnancy â‰¥16 weeks gestation&#xD;
&#xD;
          -  English speaking competency&#xD;
&#xD;
          -  Willing and able to sign consent forms&#xD;
&#xD;
          -  Agree to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women less than 18 years of age&#xD;
&#xD;
          -  IV conscious sedation&#xD;
&#xD;
          -  Known allergy to study medication (lidocaine)&#xD;
&#xD;
          -  Any women not meeting inclusion criteria above will be excluded from participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <results_first_submitted>August 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kate Ayers Shaw</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>paracervical block</keyword>
  <keyword>abortion</keyword>
  <keyword>dilation and evacuation</keyword>
  <keyword>cervical preparation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be shared with other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03356145/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>12 mL Arm</title>
          <description>Participants receive injection of 12 mL of lidocaine.</description>
        </group>
        <group group_id="P2">
          <title>20 mL Arm</title>
          <description>Participants receive injection of 20 mL of lidocaine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Allocated Intervention</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who were allocated to the intervention and for whom primary outcome measure data are available.</population>
      <group_list>
        <group group_id="B1">
          <title>12 mL Arm</title>
          <description>Participants receive injection of 12 mL of lidocaine.</description>
        </group>
        <group group_id="B2">
          <title>20 mL Arm</title>
          <description>Participants receive injection of 20 mL of lidocaine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7"/>
                    <measurement group_id="B2" value="31" spread="7"/>
                    <measurement group_id="B3" value="31" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Immediately Following Dilator Insertion</title>
        <description>The primary objective is to determine pain perceived immediately following dilator insertion measured by Visual Analogue Scale (VAS) (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
        <time_frame>Time of dilator insertion (less than 1 minute to assess pain)</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Immediately Following Dilator Insertion</title>
          <description>The primary objective is to determine pain perceived immediately following dilator insertion measured by Visual Analogue Scale (VAS) (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="21" upper_limit="58"/>
                    <measurement group_id="O2" value="49" lower_limit="26" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anticipated Pain Immediately Prior to Dilator Insertion</title>
        <description>Pain measured by VAS (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
        <time_frame>Up to 1 minute to complete survey</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Anticipated Pain Immediately Prior to Dilator Insertion</title>
          <description>Pain measured by VAS (0-100mm; 0 being no pain, 100 being worst pain imaginable).</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="28" upper_limit="62"/>
                    <measurement group_id="O2" value="58" lower_limit="43" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Satisfaction Score</title>
        <description>Global satisfaction (acceptability) of procedure reported by participant, measured by 0-100mm VAS; with anchors at 0 (&quot;worse than expected&quot;), 50 (&quot;what I expected&quot;), and 100 (&quot;better than expected&quot;).</description>
        <time_frame>Up to 1 minute to complete survey</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Satisfaction Score</title>
          <description>Global satisfaction (acceptability) of procedure reported by participant, measured by 0-100mm VAS; with anchors at 0 (&quot;worse than expected&quot;), 50 (&quot;what I expected&quot;), and 100 (&quot;better than expected&quot;).</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="39" upper_limit="91"/>
                    <measurement group_id="O2" value="53" lower_limit="44" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>Defined as time of speculum insertion</description>
        <time_frame>Up to 10 minutes</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>Defined as time of speculum insertion</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.6" upper_limit="6.9"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.6" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician-reported Ease of Insertion</title>
        <description>Measured by VAS (0-100mm; 0 being &quot;very easy&quot;, 100 being &quot;very difficult&quot;).</description>
        <time_frame>Up to 1 minute to complete survey</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician-reported Ease of Insertion</title>
          <description>Measured by VAS (0-100mm; 0 being &quot;very easy&quot;, 100 being &quot;very difficult&quot;).</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="13" upper_limit="50"/>
                    <measurement group_id="O2" value="17" lower_limit="6" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Procedural Complications</title>
        <time_frame>Up to 10 minutes</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Procedural Complications</title>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Side Effects Related to Lidocaine Administration</title>
        <description>Side effects were not necessarily considered to be adverse events by investigator.</description>
        <time_frame>Up to 10 minutes</time_frame>
        <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
        <group_list>
          <group group_id="O1">
            <title>12 mL Arm</title>
            <description>Participants receive injection of 12 mL of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>20 mL Arm</title>
            <description>Participants receive injection of 20 mL of lidocaine.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Side Effects Related to Lidocaine Administration</title>
          <description>Side effects were not necessarily considered to be adverse events by investigator.</description>
          <population>Participants who received the allocated intervention and for whom primary outcome data are available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metallic taste</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ringing in ears</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness or lightheadedness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shaky legs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Average approximately 45 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>12 mL Arm</title>
          <description>Participants receive injection of 12 mL of lidocaine.</description>
        </group>
        <group group_id="E2">
          <title>20 mL Arm</title>
          <description>Participants receive injection of 20 mL of lidocaine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Manager</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507247826</phone>
      <email>gynresearch@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

